<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Market News &#38; Stocks to Watch from StraightStocks &#187; prednisone</title>
	<atom:link href="http://www.straightstocks.com/tag/prednisone/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.straightstocks.com</link>
	<description>Leading Stock Market News, Opinions and Commentary</description>
	<lastBuildDate>Wed, 25 Nov 2009 16:10:41 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Cell Genesys, Inc. (CEGE) Receives Expected FDA Halt on Clinical Prostate Cancer</title>
		<link>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-receives-expected-fda-halt-on-clinical-prostate-cancer/</link>
		<comments>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-receives-expected-fda-halt-on-clinical-prostate-cancer/#comments</comments>
		<pubDate>Thu, 11 Sep 2008 20:24:04 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cell Genesys Inc.]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Independent Data Monitoring Committee]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[Lung Cancer]]></category>
		<category><![CDATA[Pancreatic Cancer]]></category>
		<category><![CDATA[prednisone]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Taxotere]]></category>
		<category><![CDATA[therapies for patients with cancer]]></category>
		<category><![CDATA[U.S. Food and Drug Administration]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=12315</guid>
		<description><![CDATA[ Cell Genesys (Nasdaq:CEGE) focuses on the development and commercialization of novel biological therapies for patients with cancer. The company&#8217;s lead product platform, GVAX immunotherapy for cancer, holds the potential to treat multiple types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer.
The company today announced the U.S. Food and Drug Administration has [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-receives-expected-fda-halt-on-clinical-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety</title>
		<link>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-halts-cancer-treatment-trial-to-ensure-patient-safety/</link>
		<comments>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-halts-cancer-treatment-trial-to-ensure-patient-safety/#comments</comments>
		<pubDate>Wed, 27 Aug 2008 16:49:48 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cancer Treatment]]></category>
		<category><![CDATA[Cell Genesys Inc.]]></category>
		<category><![CDATA[Independent Data Monitoring Committee]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[Lung Cancer]]></category>
		<category><![CDATA[Pancreatic Cancer]]></category>
		<category><![CDATA[prednisone]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Stephen A. Sherwin]]></category>
		<category><![CDATA[Taxotere]]></category>
		<category><![CDATA[USD]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=11996</guid>
		<description><![CDATA[Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/small-cap-and-micro-cap-stocks/cell-genesys-inc-cege-halts-cancer-treatment-trial-to-ensure-patient-safety/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
